Genetic testing company Invitae has made more than a dozen acquisitions to further its goal of democratizing genetic testing. Its latest deal, a $325 million bid to acquire Ciitizen, will add patients ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOSTON--(BUSINESS WIRE)--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation ...

Medical genetics company Invitae released a first-of-its-kind data use transparency and impact report today detailing the impact of patient data on genetic research. The report comes as concerns about ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

NEW YORK (Reuters) - Invitae Corp received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from Chapter 11 by late ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Despite efforts, Invitae shares ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

As the biotech industry's premiere manufacturer of genetic sequencing hardware and molecular biology reagent kits, Illumina powers drug development and clinical genomics alike. Between acquiring the ...

The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. In a release it put out late Tuesday ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...